Found GLP-1 review (2026): the multi-medication weight program — formulary depth, pricing complexity, and who benefits
Found offers more weight management medications in one place than most telehealth competitors — including compounded GLP-1s, orforglipron, and traditional weight medications. The value of that breadth depends entirely on whether you need it. Here is an honest breakdown.
Found is a multi-medication weight management platform with a broader drug formulary than most GLP-1 telehealth competitors — offering 10+ medications including compounded semaglutide, compounded tirzepatide, orforglipron (an oral small-molecule GLP-1 now in their formulary), and traditional weight medications like naltrexone/bupropion and metformin. The layered membership + medication cost structure means the all-in price requires careful calculation. Trustpilot 3.7/5 is below average for this category. The clinical depth for women with complex situations is a real advantage; the value proposition for straightforward GLP-1 users is less clear when cheaper single-medication programs exist.
What you will actually pay
| Plan | Monthly | Visit fee | Best for |
| Membership + compounded semaglutideGLP-1 starting point | ~$148+ | $0 (clinical visits included) | Entry GLP-1 option; membership tier determines exact total cost |
| Membership only (no medication) | $49–$199 | $0 | Women who use insurance for medication and only need clinical support + platform |
| Higher membership tier + medication | $198+ | $0 | Women who want higher-touch clinical support plus medication access |
Estimated all-in cost: ~$1,548–$3,948/yr depending on membership tier and medication. All-in GLP-1 + standard membership: ~$1,776–$2,976/yr. Higher tiers or tirzepatide increase total.
- ✓ Broadest drug formulary in category: 10+ medications beyond GLP-1s — metformin, naltrexone/bupropion, topiramate, and others
- ✓ Access to orforglipron (oral small-molecule GLP-1, no injection required)
- ✓ Clinically appropriate for women with complex needs or who have not responded to one medication
- ✓ Membership structure allows insurance-billed medication with platform-only fee
- ✓ Multi-medication capability enables stepping through options without switching platforms
- ⚑ Layered pricing (membership + medication) requires calculation to get real all-in cost
- ⚑ Trustpilot 3.7/5 — below average for this category
- ⚑ Not the cheapest path for straightforward compounded semaglutide users
- ⚑ No HRT services: women needing hormonal management need a separate provider
- ⚑ Membership tier structure adds friction vs. single all-in pricing models
What Found is
Found is a multi-medication weight management telehealth platform. Unlike GLP-1-only telehealth programs (Fridays, Amble, Henry Meds), Found's clinical model encompasses the full pharmacological toolkit for weight management: compounded semaglutide, compounded tirzepatide, orforglipron (oral GLP-1), naltrexone/bupropion, metformin, topiramate, and others. The platform's pitch is clinical matching — finding the right medication or combination for each patient rather than defaulting to one class.
Pricing: membership plus medication
Found uses a membership plus medication structure, which requires calculation to get a real all-in number:
- Membership: $49–$199/mo depending on tier (clinical support level, visit frequency)
- Compounded GLP-1 medication: ~$99/mo added to membership cost
- Example all-in: standard membership + compounded semaglutide ≈ $148+/mo
The layered structure makes direct comparison harder. At the low end (base membership + medication), Found is competitive with mid-tier GLP-1 programs. At higher membership tiers, the all-in cost rises above simpler programs. Confirm the current tier structure and medication pricing at joinfound.com before enrolling.
Orforglipron: the formulary differentiator
Orforglipron is an oral small-molecule GLP-1 receptor agonist developed by Eli Lilly — a pill, not an injection. Unlike semaglutide and tirzepatide (which are peptides and must be injected), orforglipron is taken orally. Phase 3 trial data showed meaningful weight loss, and it entered FDA review for obesity treatment. Found's inclusion of orforglipron in their formulary gives patients who cannot or prefer not to inject access to a GLP-1 class option in pill form.
This is clinically significant for women who are interested in GLP-1 therapy but needle-averse, or who have conditions that make injection complicated. Confirm with Found the current prescribing status and FDA approval timeline for orforglipron before assuming it is immediately available.
Non-GLP-1 medications: when the broader formulary matters
Found's formulary extends well beyond GLP-1s: metformin (which improves insulin sensitivity relevant to perimenopausal metabolic changes), naltrexone/bupropion (appetite regulation via different mechanisms), topiramate, and others. For women who:
- Have not responded adequately to one GLP-1 medication and want clinical support to try another
- Have contraindications to GLP-1s and want alternative weight management medication
- Have insulin resistance (common in perimenopause) that would benefit from metformin alongside or instead of a GLP-1
- Prefer to try non-injection options first
The formulary breadth translates directly to value. For women who just want compounded semaglutide and a basic clinical platform, Found's breadth doesn't matter and its all-in cost is not the cheapest option.
Patient experience: below average Trustpilot
Found's Trustpilot rating of 3.7/5 is below the 4.0+ that most GLP-1 telehealth platforms achieve. A 3.7 reflects a mixed patient experience — not a disaster, but not the strong endorsement that Fridays (4.4/5), Mochi Health, or Henry Meds show. The most common complaints in the GLP-1 telehealth category are about billing complexity and customer service responsiveness. Found's layered pricing structure may contribute to billing friction.
Frequently asked questions
What medications does Found offer beyond GLP-1s?+–
Found's formulary includes compounded semaglutide, compounded tirzepatide, orforglipron (oral GLP-1), naltrexone/bupropion (Contrave), metformin, topiramate, and others. This depth makes Found particularly useful for women with complex metabolic situations or those who have tried one medication class and need to pivot. For women who simply want compounded semaglutide, a simpler program is likely cheaper.
What is orforglipron and why does Found offer it?+–
Orforglipron is an oral small-molecule GLP-1 receptor agonist — not a peptide-based injection like semaglutide or tirzepatide, but a pill-based GLP-1 medication. It completed Phase 3 trials and entered FDA review for obesity treatment. Found's inclusion of orforglipron in the formulary gives patients who cannot or prefer not to inject access to a GLP-1 class medication in oral form. Confirm with Found the current availability and prescribing criteria.
How much does Found actually cost all-in?+–
Found uses a membership + medication structure. The membership runs $49–$199/mo depending on the tier. Compounded GLP-1 medication adds approximately $99/mo. A standard-tier membership plus compounded semaglutide runs approximately $148+/mo — confirm the current exact tiers and medication prices at joinfound.com before enrolling, as the structure has changed over time.
Is Found good for perimenopause weight gain?+–
Found addresses weight management broadly and does not specialize in menopause. The clinical team understands metabolic complexity, making it a reasonable option for women with weight gain tied to hormonal changes — but Found does not prescribe HRT. Women who need integrated hormone + weight management would benefit from a platform like Alloy or Midi Health that offers both.